Tags

Type your tag names separated by a space and hit enter

The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial.
J Dermatolog Treat. 2009; 20(1):14-8.JD

Abstract

BACKGROUND

Recently, narrow-band ultraviolet B (NB-UVB) and topical immunomodulators have been successfully used in the treatment of vitiligo.

OBJECTIVE

To determine whether the combination of pimecrolimus with NB-UVB accelerates the response time and/or improves the degree of response in patients with vitiligo.

METHODS

Sixty-eight patients with vitiligo enrolled in this randomized, double-blind, placebo-controlled study. The patients were randomized into two groups and treated with NB-UVB plus either pimecrolimus or placebo for 3 months. Tri-weekly radiation was started at 280 mJ/cm(2), with 15% increments for each subsequent treatment until erythema was reported or a maximum of 800 mJ/cm was achieved. At baseline and 6 and 12 weeks after commencement of therapy, vitiliginous patches were measured.

RESULTS

Fifty patients completed the 3-month study. No significant side effects except self-limited erythema and pruritus were observed. After 12 weeks of treatment, repigmentation of the facial lesions was higher in patients treated with combined pimecrolimus and NB-UVB compared with the placebo plus NB-UVB group (64.3 vs 25.1%) (p < 0.05%). There was no statistically significant difference in the repigmentation rate between the two groups on other body areas.

CONCLUSION

On the face, NB-UVB works better if combined with pimecrolimus 1% cream rather than used alone.

Authors+Show Affiliations

Kerman Medical University, Department of Dermatology, Kerman, Iran. iraiesfandyar@yahoo.caNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18608735

Citation

Esfandiarpour, Iraj, et al. "The Efficacy of Pimecrolimus 1% Cream Plus Narrow-band Ultraviolet B in the Treatment of Vitiligo: a Double-blind, Placebo-controlled Clinical Trial." The Journal of Dermatological Treatment, vol. 20, no. 1, 2009, pp. 14-8.
Esfandiarpour I, Ekhlasi A, Farajzadeh S, et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat. 2009;20(1):14-8.
Esfandiarpour, I., Ekhlasi, A., Farajzadeh, S., & Shamsadini, S. (2009). The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. The Journal of Dermatological Treatment, 20(1), 14-8. https://doi.org/10.1080/09546630802155057
Esfandiarpour I, et al. The Efficacy of Pimecrolimus 1% Cream Plus Narrow-band Ultraviolet B in the Treatment of Vitiligo: a Double-blind, Placebo-controlled Clinical Trial. J Dermatolog Treat. 2009;20(1):14-8. PubMed PMID: 18608735.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. AU - Esfandiarpour,Iraj, AU - Ekhlasi,Ali, AU - Farajzadeh,Saeedeh, AU - Shamsadini,Saadollah, PY - 2008/7/9/pubmed PY - 2009/9/2/medline PY - 2008/7/9/entrez SP - 14 EP - 8 JF - The Journal of dermatological treatment JO - J Dermatolog Treat VL - 20 IS - 1 N2 - BACKGROUND: Recently, narrow-band ultraviolet B (NB-UVB) and topical immunomodulators have been successfully used in the treatment of vitiligo. OBJECTIVE: To determine whether the combination of pimecrolimus with NB-UVB accelerates the response time and/or improves the degree of response in patients with vitiligo. METHODS: Sixty-eight patients with vitiligo enrolled in this randomized, double-blind, placebo-controlled study. The patients were randomized into two groups and treated with NB-UVB plus either pimecrolimus or placebo for 3 months. Tri-weekly radiation was started at 280 mJ/cm(2), with 15% increments for each subsequent treatment until erythema was reported or a maximum of 800 mJ/cm was achieved. At baseline and 6 and 12 weeks after commencement of therapy, vitiliginous patches were measured. RESULTS: Fifty patients completed the 3-month study. No significant side effects except self-limited erythema and pruritus were observed. After 12 weeks of treatment, repigmentation of the facial lesions was higher in patients treated with combined pimecrolimus and NB-UVB compared with the placebo plus NB-UVB group (64.3 vs 25.1%) (p < 0.05%). There was no statistically significant difference in the repigmentation rate between the two groups on other body areas. CONCLUSION: On the face, NB-UVB works better if combined with pimecrolimus 1% cream rather than used alone. SN - 1471-1753 UR - https://www.unboundmedicine.com/medline/citation/18608735/The_efficacy_of_pimecrolimus_1_cream_plus_narrow_band_ultraviolet_B_in_the_treatment_of_vitiligo:_a_double_blind_placebo_controlled_clinical_trial_ L2 - https://www.tandfonline.com/doi/full/10.1080/09546630802155057 DB - PRIME DP - Unbound Medicine ER -